LP17
Based on 3 publication(s) in Google Scholar
LP17 (LQVTDSGLYRCVIYHPP) is a BBB-penetrable triggering receptor expressed on myeloid cells (TREM-1) inhibitory peptide. LP17 substantially alleviates ischemia-induced infarction and neuronal injury. LP17 can get access into brain and block TREM-1.
For research use only. We do not sell to patients.
- Purity: 98.42%
- CAS No.: 887255-16-5
- Formula: C89H137N23O25S
- Molecular Weight:1961.24
-
Storage:
Sealed storage, away from moisture and light, under nitrogen.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) LP17
More
Customer Validation & Images
-
Flow Cytometry
-
In Vivo Efficacy Study
-
IF
-
IF
-
RT-PCR
Biological Activity
TREM-1[1]
LP17 (1 or 10 μM; 24 h) substantially decreases mRNA levels of pro-inflammatory cytokines and chemokines after reoxygenation and remarkably attenuates extracellular protein levels of IL-1β and IL-18 in a microglia oxygen-glucose deprivation (OGD) model[1].
LP17 (10 μM; 24 h) interacts with microglial SYK[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Primary microglia
-
Concentration:1 or 10 μM
-
Incubation Time:24 h
-
Result:Decreased mRNA levels of NLRP3, IL-1β, IL-18, IL-6, CD16, CD32, iNOS, MCP-1, CXCL-1, and CXCL-2 after reoxygenation.
-
Cell Line:Primary microglia
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Suppressed ischemia/reperfusion-induced increments in CARD9, p-p65 in CARD9/NF-κB signaling and NLRP3, ASC, cleaved caspase-1, mature IL-1β, and mature IL-18 in NLRP3/caspase-1 signaling in a microglia oxygen-glucose deprivation (OGD) model.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Adult male C57BL/6J mice (20-25 g), mice cerebral ischemia/reperfusion (I/R) model induced by middle cerebral artery occlusion (MCAO)[1]
-
Dosage:0.5 mg/kg or 1 mg/kg
-
Administration:Intranasal administration, once daily for 3 consecutive days after MCAO
-
Result:Abolished ischemia-induced TREM-1 elevation at 1 mg/kg.
Significantly reduced infarct volume by 27.3%, induced a markedly reduction in TUNEL positive cells and FJC positive neurons at 1 mg/kg.
Rescued neurological deficits and cognitive dysfunction of MCAO mice.
Inhibited microglial M1 polarization and neutrophil infiltration.
Chemical Information
-
CAS No. 887255-16-5
-
Appearance Solid
-
Molecular Weight 1961.24
-
Formula C89H137N23O25S
-
Color White to off-white
-
Synonyms
LQVTDSGLYRCVIYHPP
-
Sequence
Leu-Gln-Val-Thr-Asp-Ser-Gly-Leu-Tyr-Arg-Cys-Val-Ile-Tyr-His-Pro-Pro
-
Sequence Shortening
LQVTDSGLYRCVIYHPP
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture and light, under nitrogen
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
J Adv Res
Targeting mesenchymal monocyte-derived macrophages to enhance the sensitivity of glioblastoma to temozolomide by inhibiting TNF/CELSR2/p65/Kla-HDAC1/EPAS1 axis. [Abstract]2025 May 13:S2090-1232(25)00351-0. PMID: 40373963
LP17 purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 May 13:S2090-1232(25)00351-0. [Abstract]
Representative FCM plots and summary data showing the percentage of TREM1hi MDM in mouse model with the indicated treatment (n=5). FCM analysis revealed a significant decrease in the proportion of MES-MDM following LP17 (25 mL/kg; i.v.; once every five days) treatment in the mouse model.
LP17 purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 May 13:S2090-1232(25)00351-0. [Abstract]
Survival curve of GBM-bearing mice (n = 5 mice/group). The results showed that administration of anti-PD-1 (200 µg/mouse; i.v.; once every five days) with LP17 (25 mL/kg; i.v.; once every five days) achieved combinatorial therapeutic benefits by extending animal survival.
LP17 purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 May 13:S2090-1232(25)00351-0. [Abstract]
Representative images of multiplexed immunostaining from brains of GBM-bearing mice with anti-PD-1 and/or LP17 (25 mL/kg; i.v.; once very five days) treatment.
-
FASEB J
TREM-1 Promotes Microglial Pyroptosis and Mitochondrial Fission in Intracerebral Hemorrhage via the PI3K/AKT Pathway. [Abstract]2025 Oct 15;39(19):e71115. PMID: 41065767 -
Eur J Oral Sci
Effect of blockage of Trem1 on the M1 polarization of macrophages in the regulation dental pulp inflammation. [Abstract]2024 Oct;132(5):e13018. PMID: 39267299
LP17 purchased from MedChemExpress. Usage Cited in: Eur J Oral Sci. 2024 Oct;132(5):e13018. [Abstract]
The representative immunofluorescence images of M1 polarization of RAW264.7 macrophage with the treatment of LP17 (1 µg/µL; 48 h) or equal amount of PBS, indicated by DAPI, anti-CD68 and CD86 (n = 3). The results showed that blocking Trem1 with LP17 significantly reduced the mean fluorescence intensity of CD86.
LP17 purchased from MedChemExpress. Usage Cited in: Eur J Oral Sci. 2024 Oct;132(5):e13018. [Abstract]
LP17 (1 µg/µL; 48 h) downregulated the mRNA expression of M1 polarization-associated markers—TNF-α, iNOS, and CD86—in RAW264.7 macrophages by inhibiting Trem1.
Solvent & Solubility
H2O : 35.71 mg/mL (18.21 mM; adjust pH to 3 with CH3COOH)
DMSO : 20 mg/mL (10.20 mM; ultrasonic and warming and adjust pH to 7 with CH3COOH and heat to 37°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 0.5099 mL | 2.5494 mL | 5.0988 mL | 12.7470 mL |
| 5 mM | 0.1020 mL | 0.5099 mL | 1.0198 mL | 2.5494 mL | |
| 10 mM | 0.0510 mL | 0.2549 mL | 0.5099 mL | 1.2747 mL | |
| H2O | 15 mM | 0.0340 mL | 0.1700 mL | 0.3399 mL | 0.8498 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
LP17 Related Classifications
HY-P3400 Related Classifications
Powered by Bioz